ImmunityBio shares are trading higher after the company announced it secured $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital. The conversion of $25 million principal amount with the issuance of 4.6 million shares of the company's common stock to Nant Capital.